Bendamustine in chronic lymphocytic leukemia and non-Hodgkins lymphoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 9, 2010, Pages 1353-1365

  Ujjani, Chaitra ^a   Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

alkylating agent; antimetabolite; chemotherapy; chronic lymphocytic leukemia; non Hodgkins lymphoma; treanda

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANAPHYLAXIS; ANEMIA; ASTHENIA; BACTERIAL INFECTION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHUS CANCER; CHICKENPOX; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPERURICEMIA; INFECTION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUMOR LYSIS SYNDROME; VIRUS INFECTION; VOMITING; WEAKNESS; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; NITROGEN MUSTARD COMPOUNDS;

EID: 77956703288     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.116     Document Type: Review

References (37)

1. Hallek M, Fingerle-Rowson G, Fink A et al. Immunochemotherapy with fudarabine, cyclophosphamide and rituximab (FCR) versus fudarabine and cyclophosphamide (FC) improves response rates and progression-free survival of previously untreated subjects with advanced chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 112, 325 (2008).
2. Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fudarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood 101, 6-14 (2003).
3. Van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkin's lymphoma in patients with and without rituximab during induction: results of a prospective randomized Phase III intergroup trial. Blood 108, 3295-3301 (2006).
4. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7, 379-391 (2006).
5. Ozegowski W, Krebs D. IMET 3393, (-[1-methyl-5-bis-(2-chloroethyl)-amino- benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zbl. Pharm. 110, 1013-1019 (1971).
6. Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393, and 3943. Biochem. Biophys. Acta 287, 386-389 (1972).
7. Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14, 309-317 (2008).
8. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7, 415-421 (1996).
9. Weide R. Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma. Ther. Clin. Risk Manag 4, 1-6 (2008).
10. Kath R, Blumenstengel K, Fricke HJ et al Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J. Cancer Res. Clin. Oncol. 127, 48-54 (2001).
11. Aivado M, Schulte K, Henze L et al Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin. Oncol. 29, 19-22 (2002).
12. Bergmann MA, Goebeler ME, Herold M et al. Effcacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase I/II study of the German CLL Study Group. Haematologica 90, 1357-1364 (2005).
13. Lissitchkov T, Arnaudov G, Peytchev D et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCL in pre-treated patients with B-lymphocytic leukaemia (Binet stages B and C) requiring therapy J. Cancer Res. Clin. Oncol. 132, 99-104 (2006).
14. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pretreated low-grade non-Hodgkin's lymphomas. J. Cancer Res. Clin. Oncol. 128, 603-609 (2002).
15. Niederle N, Balleisen L, Heit W et al. Bendamustine versus fudarabine as second-line treatment for subjects with chronic lymphocytic leukemia-frst interim results of a randomized study. Ann. Oncol. 19, 379 (2008).
16. Koppler H, Heymanns J, Pandorf A et al. Bendamustine plus mitoxantrone-a new effective treatment for advanced chronic lymphocytic leukaemia: results of a Phase I/II study. Leuk. Lymphoma 45, 911-913 (2004).
17. Weide R, Pandorf A, Heymanns J et al Bendamustine/mitoxantrone/ rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final report of a pilot study. Leuk. Lymphoma 45, 2445-2449 (2004).
18. Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab for subjects with relapsed chronic lymphocytic leukemia: a multicentre Phase II trial of the German CLL Study Group (GCLLSG). Blood 112, 128, 330 (2008).
19. Fischer K, Cramer P, Stilgenbauer S et al. Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: a multicenter Phase II trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 205).
20. Knauf WU, Lissichkov T, Aldaoud A et al Bendamustine versus chlorambucil in B-cell chronic lymphocytic leukemia (CLL): an updated analysis from an international Phase III study. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 2091).
21. Heider A, Niederle N. Effcacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 12, 725-729 (2001).
22. Weidmann E, Kim SZ, Rost A et al Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann. Oncol. 13, 1285-1289 (2002).
23. Friedberg JW, Cohen P, Chen L et al Bendamustine in patients with rituximab-refractory and alkylator-refractory indolent, and transformed non-Hodgkin's lymphoma: results from a Phase II multicenter single-agent study. J. Clin. Oncol. 26, 204-210 (2008).
24. Kahl B, Bartlett NL, Leonard JP et al Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkins lymphoma: results from a multicenter study. Cancer 116, 106-114 (2010).
25. Cheson B, Friedberg J, Kahl B et al Bendamustine produces durable responses with an acceptable long-term safety profle in patients with rituximab-refractory non-Hodgkins lymphoma: a pooled analysis. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 2681).
26. Ogura M, Uchida T, Ando K et al Bendamustine is highly effective for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: fnal results of a Japanese multicenter Phase II study. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 3694).
27. Koenigsmann M, Knauf WU, Herold M et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma: a multicenter Phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk. Lymphoma 45, 1821-1827 (2004).
28. Rummel M, Al-Batran S, Kim S et al. Bendamustine plus rituximab is effective and has a favorable toxicity profle in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 3383-3389 (2005).
29. Robinson K, Williams M, Van Der Jagt R et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 26, 4473-4479 (2008).
30. Weide R, Hess G, Koppler H et al. High anti-lymphoma activity of bendamustine/ mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle-cell lymphomas: a multicenter Phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk. Lymphoma 48, 1299-1306 (2007).
31. Friedberg J, Vose J, Kelly J et al. Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a multicenter Phase II clinical trial. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 924).
32. Fowler N, Kahl B, Rosen P et al. Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 933).
33. Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkins lymphoma and mantle-cell lymphoma: results of a randomised Phase III trial (OSHO#19). J. Cancer Res. Clin. Oncol 132, 105-112 (2006).
34. Rummel M, Niederle N, Maschmeyer G et al. Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: fnal results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 405).
35. Cheson B, Kroll M. Bendamustine induced neurotoxicity Clin. Adv. Hematol. Oncol 11, 743-746 (2009).
36. Cheson B, Wendtner C, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple myeloma: treatment recommendations from an international consensus panel. Clin. Lymphoma Myeloma Leuk. 10, 21-27 (2010).
37. Moskowitz A, Hamlin P Jr, Gerecitano J et al. Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 720).